Silencing of transforming growth factor-β1 in situ by RNA interference for breast cancer: Implications for proliferation and migration in vitro and metastasis in vivo

Clinical Cancer Research

Volumn 14, Issue 15, 2008, Pages 4961-

  Moore, Lakisha D ^a   Isayeva, Tatyana ^a   Siegal, Gene P ^a   Ponnazhagan, Selvarangan ^a  

^a University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; SMAD2 PROTEIN; SMALL INTERFERING RNA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 2; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA2; TRANSFORMING GROWTH FACTOR BETA3;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER GROWTH; CANCER INVASION; CANCER MODEL; CELL MIGRATION; CELL PROLIFERATION; CLONE; CONTROLLED STUDY; DRUG TARGETING; ENZYME ACTIVATION; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; LUNG METASTASIS; METASTASIS INHIBITION; MOUSE; NEGATIVE FEEDBACK; NONHUMAN; PRIMARY TUMOR; PRIORITY JOURNAL; RNA INTERFERENCE; SIGNAL TRANSDUCTION; ANIMAL; BREAST TUMOR; CANCER TRANSPLANTATION; CELL MOTION; GENETICS; METABOLISM; METASTASIS; NUDE MOUSE; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; FEMALE; HUMANS; MICE; MICE, NUDE; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASM TRANSPLANTATION; RNA INTERFERENCE; TRANSFORMING GROWTH FACTOR BETA1;

EID: 51049111434     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-4604     Document Type: Article

References (51)

1. Donovan D, Harmey JH, Toomey D, Osborne DH, Redmond HP, Bouchier-Hayes DJ. TGFβ-1 regulation of VEGF production by breast cancer cells. Ann Surg Oncol 1997;4:621-7.
2. Huber MA, Kraut N, Beug H. Molecular requirements for epithelial-mesenchymal transition during tumor progression. Curr Opin Cell Biol 2005;17:548-58.
3. Jeon SH, Chae BC, Kim HA, et al. Mechanisms underlying TGF-β1 -induced expression of VEGF and Flk-1 in mouse macrophages and their implications for angiogenesis. J Leukoc Biol 2007;81:557-66.
4. Pepper MS. Transforming growth factor-β: vasculogenesis, angiogenesis, and vessel wall integrity. Cytokine Growth Factor Rev 1997;8:21-43.
5. Muraoka RS, Dumont N, Ritter CA, et al. Blockade of TGF- β inhibits mammary tumor cell viability, migration, and metastases. J Clin Invest 2002;109:1551-9.
6. Kajdaniuk M, Swietochowska, Ostrowska Z, et al. Plasma transforming growth factor β1 in breast cancer patients treated with CMF chemotherapy. J Clin Pharm Ther 2000;25:291-4.
7. Sheen-Chen SM, Chen HS, Sheen CW, Eng HL, Chen WJ. Serum levels of transforming growth factor 1 in patients with breast cancer. Arch Surg 2001;136: 937-40.
8. Ivanovic V, Demajo M, Krtolica K, et al. Elevated plasma TGF-β1 levels correlate with decreased survival of metastatic breast cancer patients. Clin Chim Acta 2006;371:191-3.
9. Aiping H. Drug resistance and gene amplification potential regulated by transforming growth factor (VI gene expression. Cancer Res 1995;55:1758-62.
10. Teicher BA, Maehara Y, Kakeh Y, et al. Reversal of in vivo drug resistance by the transforming growth factor-βinhibitor decorin. lnt J Cancer 1998;71:49-58.
11. Bierie B, Moses HL. TGF-β and cancer. Cytokine Growth Factor Rev 2006:17:29-40.
12. Blobe GC, Schiemann WP, Lodish HF Role of transforming growth factor β in human disease. N Engl J Med 2000;342:1350-8.
13. Elliott RL, Blobe GC. Role of transforming growth factor β in human cancer. J Clin Oncol 2005:23: 2078-93.
14. Bandyopadhyay A, Agyin J, Wang L, etal. Inhibition of pulmonary and skeletal metastasis by a transforming growth factor-β type I receptor kinase inhibitor. Cancer Res 2006:66:6714-21.
15. Siegel PM, Shue W, Cardiff RD, Muller WJ, Massagué J. Transforming growth factor β signaling impairs Neu-induced mammary tumorigenesis while promoting pulmonary metastasis. Proc Natl Acad Sci USA2003;100:8430-5.
16. Boyce BF, Yoneda T, Guise TA. Factors regulating the growth of metastatic cancer in bone. Endocr Relat Cancer 1999;6:333-47.
17. Cicek M, Oursler M. Breast cancer bone metastasis and current small therapeutics. Cancer Metastasis 2006;25:635-44.
18. Smid M, Wang Y, Klijn JG, et al. Genes associated with breast cancer metastatic to bone. J Clin Oncol 2006;24:2261-7.
19. Chang CF, Westbrook R, Ma J, Cao D. Transforming growth factor-β signaling in breast cancer. Front Biosci 2007;12:4393-401.
20. Annes JP, Munger JS, Rifkin DB. Making sense of latent TGFβ activation. J Cell Sci 2003;116:217-24.
21. Dumont N, Arteaga CL. Transforming growth factor- β and breast cancer: Tumor promoting effects of transforming growth factor-β Breast Cancer Res 2000;2: 125-32.
22. Iyer S, Wang ZG, Akhtari M, Zhao W, Seth P. Targeting TGFβ signaling for cancer therapy. Cancer Biol Ther 2005;4:261-66.
23. Lutz M, Knaus P. Integration of the TGF-β pathway into the cellular signaling network. Cell Signal 2002: 14;977-88.
24. Remy I, Montmarquette A, Michnick SW. PKB/Akt modulates TGF-β signaling through a direct interaction with Smad3. Nat Cell Biol 2004;6:358-65.
25. Glick AB.TGFβ1, back to the future: revisiting its role as a transforming growth factor. Cancer Biol Ther 2004;3:276-83.
26. Bakin AV, Tomlinson AK, Bhowmick NA, Moses HL, Arteaga CL. Phosphatidylinositol 3-kinase function is required for transforming growth factor β-mediated epithelial to mesenchymal transition and cell migration. J Biol Chem 2000;275:36803-10.
27. Arteaga CL, Hurd SD, Winnier AR, Johnson MD, Fendly BM, Forbes JT. Anti-transforming growth factor (TGF) -β antibodies inhibit breast cancer cell tumorigenicity and increase mouse spleen natural killer cell activity. Implications for a possible role of tumor cell/host TGF-β interactions in human breast cancer progression. J Clin Invest 1993;92:2569-76.
28. Dumont N, Bakin AV, Arteaga CL. Autocrine transforming growth factor-β signaling mediates Smadindependent motility in human cancer cells. J Biol Chem 2003;278:3275-85.
29. Lamouille S, Derynck R. Cell size and invasion in TGF-{β} induced epithelial to mesenchymal transition is regulated by activation of the mTOR pathway. J Cell Biol 2007;178:437-51.
30. Xie L, Law BK, Chytil AM, Brown KA, Aakre ME, Moses HL. Activation of the Erk pathway is required for TGF- & beta1-induced EMT in vitro. Neoplasia 2004;6: 603-10.
31. Atfi A, Dejelloul S, Chastre E, Davis R, Gespach C. Evidence for a role of Rho-like GTPases and stressactivated protein kinase/c-Jun N-terminal kinase (SAPK/JNK) in transforming growth factor β-mediated signaling. J Biol Chem 1997;272:1429-32.
32. Mulder KM. Role of Ras and Mapks in TGFβ signaling. Cytokine Growth Factor Rev 2000;11:23-35.
33. Wilkes MC, Mitchell H, Penheiter SG, et al. Transforming growth factor-β activation of phosphatidylinositol 3-kinase is independent of Smad2 and Smad3 and regulates fibroblast responses via p21- activated kinase-2. Cancer Res 2005;65:10431-40.
34. Yingling JM, Blanchard KL, Sawyer JS. Development of TGF- β signaling inhibitors for cancer therapy. Nat Rev Drug Discov 2004:3:1011-22.
35. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real time quantitative PCR and the 2-ΔΔCT Method. Methods 2001;25:402-8.
36. Mahendra G, Kumar S, Isayeva T, Ponnazhagan S. Antiangiogenic cancer gene therapy by adeno-associated virus 2-mediated stable expression of the soluble FMS-like tyrosine kinase 1 receptor. Cancer Gene Ther 2005;12:26-34.
37. Derynck R, Zhang YE. Smad-dependent and Smadindependent pathways in TGF-β family signaling. Nature 2003;425:577-84.
38. Roberts AB, Thompson NL, Heine U, Flanders C, Sporn MB. Transforming growth factor- β: possible roles in carcinogenesis. Br J Cancer 1998;57:594-600.
39. Gold L. The role for transforming growth factor-β. (TGF-β) in human cancer. Crit Rev Oncog 1999;10: 303-60.
40. Kamaraju AK, Roberts AB. Role of Rho/ROCK and p38 MAP kinase pathways in transforming growth factor-β-mediated Smad-dependent growth inhibition of human breast carcinoma cells in vivo. J Biol Chem 2005;280:1024-36.
41. Mucsi I, Skorecki KL, Goldberg HJ. Extracellular signal-regulated kinase and the small GTP-binding protein, Rac, contribute to the effects of transforming growth factor- β1 on gene expression. J Biol Chem 1996;271:16567-72.
42. Safina A, Vandette E, Bakin AV. ALK5 promotes tumor angiogenesis by upregulating matrix metalloproteinase-9 in tumor cells. Oncogene 2007;26: 2407-22.
43. Yi JY, Shin I, Arteaga CL. Type I transforming growth factor β receptor binds to and activates phosphatidylinositol 3-kinase. J Biol Chem 2005; 280:10870-6.
44. Cho HJ, Yoo J. Rho activation is required for transforming growth factor-β-induced epithelial-mesenchymal transition in lens epithelial cells. Cell Biol Int 2007;31:1225-30.
45. Song K, Wang H, Krebs TL, Danielpour D. Novel roles of Akt and mTOR in suppressing TGF-β/ALK5-mediated Smad3 activation. EMBO J 2006;25:58-69.
46. Involvement of PI3K/Akt pathway in TGF-β2 mediated epithelial mesenchymal transition in human lens epithelial cells. Ophthalmic Res 2008;40.69-76
47. McCubrey JA, Steelman LS. Abrams SL. Libra M Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance. Adv Enzyme Regul 2006;46:249-79.
48. Arteaga CL. Inhibition of TGFβ signaling in cancer therapy. Curr Opin Genet Dev 2006;16:30-7
49. Dong M. How T, Kirkbride KC, et al. The type III TGF-β receptor suppresses breast cancer progression. J Clin Invest 2007;117:206-17
50. Dumont N. Artega CL. Targeting the TGF β signaling network in human neoplasia Cancer Cell 2003:3 531-6.
51. Uhl M, Aulwurm S, Wischussen J. Weller M. SD- 208. a novel transforming growth factor β receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo. Cancer Res 2004; 64:7954-61